A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Nov 2017
At a glance
- Drugs Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Janssen Research & Development
- 03 Feb 2017 This trial has been completed in Czech Republic.
- 11 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 26 Nov 2015 New source identified and integrated- United Kingdom Clinical Research Network record.